Chemotherapy-Induced Nausea Vomiting (CINV) Drugs Market Scope
Chemotherapy-induced nausea and vomiting (CINV) is the term for nausea and vomiting (emesis) produced by cancer medications (CINV). Patients may have nausea and vomiting within 24 hours of starting chemotherapy (acute) or after 24 hours of starting chemotherapy (delayed). Chemotherapy-induced nausea and vomiting cause cancer patients to postpone or refuse chemotherapy treatment. The market will grow due to an increase in the number of patients having chemotherapy, increased compliance with chemotherapy medications, and the introduction of very promising novel drugs. The development of a company's product portfolio market, as well as new advancements in delivery type, will also heighten various opportunities that will begin to germinate in chemotherapy-induced nausea and vomiting medications market throughout the projected period.
The Chemotherapy-Induced Nausea Vomiting (CINV) Drugs market study is segmented by Type (Acute Emesis, Delayed Emesis, Anticipatory Emesis and Refractory Emesis) and major geographies with country level break-up.
Mergers and acquisitions, expansions, investments, new service launches, and collaborations are some of the companies' preferred market-exploration strategies. To Competitive advantage through synergy, players are growing and acquiring businesses in new geographies. The company is contributing its share to growing the market. There are several significant participants in the CINV Drug industry, which is moderately competitive. Merck & Co., Inc., GlaxoSmithKline plc, Heron Therapeutics, Inc., Helsinn Holding S.A., Baxter Healthcare, Sandoz (Novartis AG), Orchid Healthcare, Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals, and Sun Pharma are some of the market leaders.
Helsinn Holding S.A. (Switzerland), Tesaro, Inc (United States), Kyowa Kirin, Inc. (India), Pfizer Inc. (United States), GlaxoSmithKline plc. (United Kingdom), AbbVie Inc. (United States), Merck & Co., Inc. (United States), Bausch Health Companies Inc. (Canada), Novartis AG (Switzerland) and Ono Pharmaceutical Co., Ltd. (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Camurus AB (Sweden) and Heron Therapeutics, Inc. (United States).
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
Segmentation Overview
AMA Research has segmented the market of Global Chemotherapy-Induced Nausea Vomiting (CINV) Drugs market by Type, Application and Region.
On the basis of geography, the market of Chemotherapy-Induced Nausea Vomiting (CINV) Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In Jan 2020, Pfizer Inc. has bought Array BioPharma Inc., a pharmaceutical business based in the United States. This acquisition is expected to boost the company's creative biopharmaceutical business and help satisfy unmet medical requirements for diseases including cancer and other rare diseases.
Market Drivers
- Online Pharmacies' Easy Availability of Chemotherapy-Induced Nausea and Vomiting Treatment Medications Will Improve Sales
- Accelerated Drug Approvals Will Boost Sales of Chemotherapy-Induced Nausea and Vomiting Therapies
Opportunities
- Advanced Technology Developments to Discover New High Potential Drugs Create an Opportunity
- Increasing Drug Manufactures and Increase Funding to Prevent Cancer Cases
Restraints
- Regulations Governing CINV Medications' Access and Availability May Hinder Market Growth
- High Price of CINV Drugs
Challenges
- High Competition in the Market
Key Target Audience
Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors